Liora Schultz News Today

Higher doses of tisagenlecleucel improved survival outcomes in pediatric patients with B-ALL without increasing toxicity.

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.